What emerging precision diagnostic tests are available to predict transformation probability from marginal zone...

I apologize, but I believe there may be some confusion. Marginal zone lymphoma (MZL) and diffuse large B-cell lymphoma (DLBCL) are distinct types of non-Hodgkin lymphoma, rather than one transforming into the other. MZL does not typically transform into DLBCL.

According to the Leukemia & Lymphoma Society, MZL is an indolent (slow-growing) B-cell lymphoma that can be divided into three subtypes: extranodal MZL, nodal MZL, and splenic MZL. In contrast, DLBCL is an aggressive (fast-growing) B-cell lymphoma.

While there are no specific biomarker tests to predict transformation from MZL to DLBCL, the NCCN Guidelines for B-Cell Lymphomas recommend the following diagnostic tests for both MZL and DLBCL:

1. Excisional or incisional lymph node biopsy
2. Immunohistochemistry panel
3. Flow cytometry
4. Molecular analysis (e.g., FISH, karyotype, sequencing)
5. Imaging studies (e.g., CT, PET/CT, MRI)

These tests help determine the specific subtype of lymphoma and guide treatment decisions. However, they are not used to predict transformation between different types of lymphoma.

If you have concerns about your specific diagnosis or potential for disease progression, it's essential to discuss these with your healthcare team. They can provide personalized guidance based on your individual case and the most current medical evidence.